NCX 1022

Drug Profile

NCX 1022

Alternative Names: NCX-1022; Nitric oxide-donating derivative of hydrocortisone - NicOx; NO-hydrocortisone

Latest Information Update: 10 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Developer Ferrer; NicOx
  • Class Antipsoriatics; Glucocorticoids; Pregnenediones
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Seborrhoeic dermatitis

Most Recent Events

  • 10 Oct 2007 No development reported - Phase-I for Psoriasis in France (Topical)
  • 10 Oct 2007 No development reported - Phase-II for Seborrhoeic dermatitis in France (Topical)
  • 15 Sep 2005 NicOx expands its existing collaboration with Ferrer Grupo International for the research, development and marketing of nitric oxide-donating corticosteroids for dermatological indications, including NCX 1022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top